Patents by Inventor Andrew P. Combs

Andrew P. Combs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclylamines as PI3K inhibitors
    Patent number: 10646492
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: May 12, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Song Mei, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks
  • TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS
    Publication number: 20200131195
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 30, 2020
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, JR., James D. Rodgers
  • PYRIMIDINONES AS PI3K INHIBITORS
    Publication number: 20200123176
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: August 20, 2019
    Publication date: April 23, 2020
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Tricyclic heterocycles as BET protein inhibitors
    Patent number: 10618910
    Abstract: The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: April 14, 2020
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks
  • HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20200102315
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 2, 2019
    Publication date: April 2, 2020
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
  • Aza-heteroaryl compounds as PI3K-gamma inhibitors
    Patent number: 10596184
    Abstract: The present invention provides aza-heteroaryl derivatives of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, W, R4, R5, and R6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (PI3K?) and are useful in the treatment of diseases related to the activity of PI3K? including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: March 24, 2020
    Assignee: Incyte Corporation
    Inventors: Ge Zou, Andrew P. Combs
  • CRYSTALLINE FORMS OF A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR
    Publication number: 20200071335
    Abstract: The present invention relates to salts and crystalline forms of 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, and crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, which are PI3K inhibitors useful in the treatment of cancer and other diseases.
    Type: Application
    Filed: September 4, 2019
    Publication date: March 5, 2020
    Inventors: Brent Douty, David M. Burns, Andrew P. Combs, Zhongjiang Jia, Daniel Levy, Eddy W. Yue
  • 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
    Publication number: 20200048251
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: October 21, 2019
    Publication date: February 13, 2020
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, JR., Nikoo Falahatpisheh
  • HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20200031837
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 1, 2019
    Publication date: January 30, 2020
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS
    Publication number: 20200002295
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: July 1, 2019
    Publication date: January 2, 2020
    Inventors: Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue
  • PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS
    Publication number: 20190359592
    Abstract: The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3K?) and are useful in the treatment of diseases related to the activity of PI3K? including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: March 29, 2019
    Publication date: November 28, 2019
    Inventors: Richard B. Sparks, Stacey Shepard, Andrew P. Combs, Andrew W. Buesking, Lixin Shao, Haisheng Wang, Nikoo Falahatpisheh
  • Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
    Patent number: 10479803
    Abstract: This application relates to derivatives of Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K, and compositions and methods of treatment related thereto.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: November 19, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Andrew P. Combs
  • Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors
    Patent number: 10479795
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: November 19, 2019
    Assignee: Incyte Corporation
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
  • Heterocyclic compounds as PI3K-? inhibitors
    Patent number: 10472368
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: November 12, 2019
    Assignee: Incyte Corporation
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
    Patent number: 10472358
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: November 12, 2019
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
  • Tricyclic heterocycles as BET protein inhibitors
    Patent number: 10464947
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: November 5, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
  • 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase
    Publication number: 20190298700
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Application
    Filed: June 19, 2019
    Publication date: October 3, 2019
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
  • HETEROCYCLYLAMINES AS PI3K INHIBITORS
    Publication number: 20190298724
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: June 19, 2019
    Publication date: October 3, 2019
    Inventors: Richard B. Sparks, Andrew P. Combs, Brent Douty, Yun-Long Li, Song Mei, Eddy W. Yue
  • Pyrimidinones as PI3K inhibitors
    Patent number: 10428087
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: October 1, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20190276435
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: March 7, 2019
    Publication date: September 12, 2019
    Inventors: Stacey Shepard, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao